Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
Not establishedNo board position is currently listed on this profile
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Eric Warren, R.Ph. has served as Chief Commercial Officer since April 2025, previously serving as Chief Commercial Officer at Esperion Therapeutics from March 2022 to April 2025. He also held VP roles at Nabriva Therapeutics and Sanofi, and spent over 12 years at Merck & Co. in roles of increasing responsibility.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Executive appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Connections

Explore the roles, education and affiliations published in this record.

Mineralys Therapeutics, Inc.

Open Mineralys Therapeutics, Inc. profile →

Chief Commercial Officer at Mineralys Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-26

Mineralys Therapeu…Mineralys Therapeutics, Inc.Eric Warren

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec Form OwnershipPublic profile sourceSupports Chief Commercial Officer at Mineralys Therapeutics, Inc. (NASDAQ: MLYS).Open sourceSource 2 · Sec FilingMLYS 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:eric-warren
Record version
public-0

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Open source

    sec form ownership · Source published: Jul 21, 2026 · Retrieved: Jul 29, 2026

    Supports 1 claim
    • Professional Role: Chief Commercial Officer at Mineralys Therapeutics, Inc. · Claim reviewed: May 15, 2026

  2. MLYS 10-K executive officers

    sec filing · Source published: Mar 12, 2026 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Mineralys Therapeutics, Inc. · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Commercial Officer · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at Mineralys Therapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · Source reportedExecutive title: Chief Commercial Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

View all sources2 records
  1. https://www.sec.gov/Archives/edgar/data/1933414/000191604826000009/wk-form4_1784846362.xml

    Sec Form Ownership · Tier not stated · Reviewed Jul 29, 2026

    Supports: Chief Commercial Officer at Mineralys Therapeutics, Inc. (NASDAQ: MLYS)

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background